Daiwa Securities Group Inc. Acquires 1,828 Shares of IQVIA Holdings Inc. (NYSE:IQV)

by · The Cerbat Gem

Daiwa Securities Group Inc. boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 5.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,651 shares of the medical research company’s stock after purchasing an additional 1,828 shares during the quarter. Daiwa Securities Group Inc.’s holdings in IQVIA were worth $8,922,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in IQV. First Foundation Advisors boosted its position in shares of IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after acquiring an additional 43 shares during the last quarter. Invera Wealth Advisors LLC boosted its holdings in shares of IQVIA by 0.3% during the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after purchasing an additional 46 shares during the last quarter. Oregon Public Employees Retirement Fund increased its holdings in shares of IQVIA by 0.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after purchasing an additional 48 shares during the last quarter. Continuum Advisory LLC lifted its position in shares of IQVIA by 3.3% in the second quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock worth $325,000 after buying an additional 49 shares in the last quarter. Finally, Clear Harbor Asset Management LLC boosted its stake in IQVIA by 1.3% during the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after buying an additional 50 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent research reports. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. The Goldman Sachs Group lowered their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Robert W. Baird decreased their target price on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. JPMorgan Chase & Co. dropped their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Finally, BTIG Research decreased their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

Get Our Latest Stock Analysis on IQV

IQVIA Trading Up 1.1 %

NYSE IQV opened at $204.02 on Tuesday. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company’s 50-day moving average price is $221.96 and its 200-day moving average price is $226.98. The stock has a market cap of $37.03 billion, a PE ratio of 26.77, a PEG ratio of 2.08 and a beta of 1.51. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Stories